Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 5/2016

01-05-2016 | Review

Current Perspectives of Prophylaxis and Management of Acute Infective Endophthalmitis

Authors: Paris Tranos, Nikolaos Dervenis, Athanasios N. Vakalis, Solon Asteriadis, Panagiotis Stavrakas, Anastasios G. P. Konstas

Published in: Advances in Therapy | Issue 5/2016

Login to get access

Abstract

Endophthalmitis is an intraocular inflammatory condition which may or may not be caused by infective agents. Noninfectious (sterile) endophthalmitis may be attributable to various causes including postoperative retained soft lens matter or toxicity following introduction of other agents into the eye. Infectious endophthalmitis is further subdivided into endogenous and exogenous. In endogenous endophthalmitis there is hematogenous spread of organisms from a distant source of infection whereas in exogenous endophthalmitis direct microbial inoculation may occur usually following ocular surgery or penetrating eye injury with or without intraocular foreign bodies. Acute infective endophthalmitis is usually exogenous induced by inoculation of pathogens following ocular surgery, open-globe injury and intravitreal injections. More infrequently the infective source is internal and septicemia spreads to the eye resulting in endogenous endophthalmitis. Several risk factors have been implicated including immunosuppression, ocular surface abnormalities, poor surgical wound construction, complicated cataract surgery with vitreous loss and certain types of intraocular lens. Comprehensive guidelines and recommendations on prophylaxis and monitoring of surgical cases have been proposed to minimize the risk of acute endophthalmitis. Early diagnosis and prompt management of infective endophthalmitis employing appropriately selected intravitreal antibiotics are essential to optimize visual outcome.
Literature
1.
Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. Dublin: European Society of Cataract and Refractive Surgeons; 2013.
2.
Pathengay A, Flynn HW Jr, Isom RF, Miller D. Endophthalmitis outbeaks following cataract surgery: causative organisms, etiologies and visual acuity outcomes. J Cataract Refract Surg. 2012;38(7):1278–82.PubMedCrossRef
3.
Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. 2012;96(6):862–6.PubMedCrossRef
4.
Sadaka A, Durand ML, Gilmore MS. Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host–microbe interactions in intraocular infection. Prog Retin Eye Res. 2012;31(4):316–31.PubMedPubMedCentralCrossRef
5.
Keay L, Gower EW, Cassard SD, Tielsch JM, Schein OD. Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries. Ophthalmology. 2012;119(5):914–22.PubMedPubMedCentralCrossRef
6.
Freeman EE, Roy-Gagnon M-H, Fortin E, Gauthier D, Popescu M, Boisjoly H. Rate of endophthalmitis after cataract surgery in Quebec, Canada, 1996–2005. Arch Ophthalmol. 2010;128(2):230–4.PubMedCrossRef
7.
Kodjikian L, Salvanet-Bouccara A, Grillon S, Forestier F, Seegmuller J-L, Berdeaux G, et al. Postcataract acute endophthalmitis in France: national prospective survey. J Cataract Refract Surg. 2009;35(1):89–97.PubMedCrossRef
8.
Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123(5):613–20.PubMedCrossRef
9.
Leopold I. Incidence of endophthalmitis after cataract surgery. Trans Ophthalmol Soc UK. 1971;191:575–609.
10.
Aaberg TM, Flynn HW, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey: a 10-year review of incidence and outcomes. Ophthalmology. 1998;105(6):1004–10.PubMedCrossRef
11.
Levison AL, Mendes TS, Bhisitkul R. Post procedural endophthalmitis: a review. Expert Rev Ophthalmol. 2013;8(1):45–62.CrossRef
12.
Chen X, Adelman RA. Microbial spectrum and resistance patterns in endophthalmitis: a 21-year (1988–2008) review in Northeast United States. J Ocul Pharmacol Ther. 2012;28(4):329–34.PubMedCrossRef
13.
Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27(6):662–80.PubMedCrossRef
14.
Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122(1):1–17.PubMedCrossRef
15.
Johnson MW, Doft BH, Kelsey SF, Barza M, Wilson LA, Barr CC, et al. The endophthalmitis vitrectomy study: relationship between clinical presentation and microbioloaic spectrum. Ophthalmology. 1997;104(2):261–72.PubMedCrossRef
16.
Charles QY, Ta CN. Prevention of postcataract endophthalmitis: evidence-based medicine. Curr Opin Ophthalmol. 2012;23(1):19–24.CrossRef
17.
Al-Mezaine HS, Kangave D, Al-Assiri A, Al-Rajhi AA. Acute-onset nosocomial endophthalmitis after cataract surgery: incidence, clinical features, causative organisms, and visual outcomes. J Cataract Refract Surg. 2009;35(4):643–9.PubMedCrossRef
18.
Lundström M, Wejde G, Stenevi U, Thorburn W, Montan P. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology. 2007;114(5):866–70.PubMedCrossRef
19.
Group EES. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978–88.CrossRef
20.
Brazitikos P, Balidis M, Tranos P, Androudi S, Papadopoulos N, Tsinopoulos I, Stangos N. Sulcus implantation of a 3-piece, 6.0 mm optic, hydrophobic foldable acrylic intraocular lens in phacoemulsification complicated by posterior capsule rupture. J Cataract Refract Surg. 2002;28(9):1618–22.PubMedCrossRef
21.
Galor A, Goldhardt R, Wellik SR, Gregori NZ, Flynn HW. Management strategies to reduce risk of postoperative infections. Curr Ophthalmol Rep. 2013;1(4):161–8.
22.
Miño DKH, Ta CN, Froehlich SJ, Schaller UC, Engelbert M, Klauss V, et al. Prospective study of risk factors for conjunctival bacterial contamination in patients undergoing intraocular surgery. Eur J Ophthalmol. 2008;19(5):717–22.
23.
de Kaspar HM, Shriver EM, Nguyen EV, Egbert PR, Singh K, Blumenkranz MS, et al. Risk factors for antibiotic-resistant conjunctival bacterial flora in patients undergoing intraocular surgery. Graefe’s Arch Clin Exp Ophthalmol. 2003;241(9):730–3.CrossRef
24.
Tan CS, Wong HK, Yang FP. Epidemiology of postoperative endophthalmitis in an Asian population: 11-year incidence and effect of intracameral antibiotic agents. J Cataract Refract Surg. 2012;38(3):425–30.PubMedCrossRef
25.
Keynan Y, Finkelman Y, Lagacé-Wiens P. The microbiology of endophthalmitis: global trends and a local perspective. Eur J Clin Microbiol Infect Dis. 2012;31(11):2879–86.PubMedCrossRef
26.
Miller JJ, Scott IU, Flynn HW, Smiddy WE, Newton J, Miller D. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139(6):983–7.PubMedCrossRef
27.
Parmar P, Salman A, Kaliamurthy J, Prasanth DA, Thomas PA, Jesudasan CAN. Anterior chamber contamination during phacoemulsification and manual small-incision cataract surgery. Am J Ophthalmol. 2006;141(6):1160–1.PubMedCrossRef
28.
Romero-Aroca P, Méndez-Marin I, Salvat-Serra M, Fernández-Ballart J, Almena-Garcia M, Reyes-Torres J. Results at seven years after the use of intracamerular cefazolin as an endophthalmitis prophylaxis in cataract surgery. BMC Ophthalmol. 2012;12(1):2.PubMedPubMedCentralCrossRef
29.
Barreau G, Mounier M, Marin B, Adenis J-P, Robert P-Y. Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study. J Cataract Refract Surg. 2012;38(8):1370–5.PubMedCrossRef
30.
Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, et al. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 2003;110(10):1946–51.PubMedCrossRef
31.
Group EVS. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–96.
32.
Sheng Y, Sun W, Gu Y, Lou J, Liu W. Endophthalmitis after cataract surgery in China, 1995–2009. J Cataract Refract Surg. 2011;37(9):1715–22.PubMedCrossRef
33.
Gribomont A. General review-post-cataract surgery endophthalmitis: an update. Bull Soc Belge Ophtalmol. 2009;311:43.PubMed
34.
Wykoff CC, Flynn HW, Miller D, Scott IU, Alfonso EC. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology. 2008;115(9):1501–7. e2.
35.
Kuhn F, Gini G. Ten years after … are findings of the Endophthalmitis Vitrectomy Study still relevant today? Graefe’s Arch Clin Exp Ophthalmol. 2005;243(12):1197–9.
36.
Taban M, Behrens A, Newcomb RL, Nobe MY, McDonnell PJ. Incidence of acute endophthalmitis following penetrating keratoplasty: a systematic review. Arch Ophthalmol. 2005;123(5):605–9.PubMedCrossRef
37.
Hood CT, Lee BJ, Jeng BH. Incidence, occurrence rate, and characteristics of suture-related corneal infections after penetrating keratoplasty. Cornea. 2011;30(6):624–8.PubMedCrossRef
38.
Chen JY, Jones MN, Srinivasan S, Neal TJ, Armitage WJ, Kaye SB, et al. Endophthalmitis after penetrating keratoplasty. Ophthalmology. 2015;122(1):25–30.PubMedCrossRef
39.
Kloess PM, Stulting RD, Waring GO, Wilson LA. Bacterial and fungal endophthalmitis after penetrating keratoplasty. Am J Ophthalmol. 1993;115(3):309–16.PubMedCrossRef
40.
Kunimoto DY, Tasman W, Rapuano C, Recchia F, Busbee B, Pearlman R, et al. Endophthalmitis after penetrating keratoplasty: microbiologic spectrum and susceptibility of isolates. Am J Ophthalmol. 2004;137(2):343–5.PubMedCrossRef
41.
Hassan SS, Wilhelmus KR, Dahl P, Davis GC, Roberts RT, Ross KW, et al. Infectious disease risk factors of corneal graft donors. Arch Ophthalmol. 2008;126(2):235–9.PubMedPubMedCentralCrossRef
42.
Bor E, Kremer I. Endophthalmitis and wound dehiscence following late removal of penetrating keratoplasty sutures. Ophthalmic Surg Lasers Imaging. 2010;42(3):234–40.CrossRef
43.
Shih CY, Ritterband DC, Rubino S, Palmiero P-M, Jangi A, Liebmann J, et al. Visually significant and nonsignificant complications arising from Descemet stripping automated endothelial keratoplasty. Am J Ophthalmol. 2009;148(6):837–43.PubMedCrossRef
44.
Ramchandran RS, DiLoreto DA, Chung MM, Kleinman DM, Plotnik RP, Graman P, et al. Infectious endophthalmitis in adult eyes receiving Boston type I keratoprosthesis. Ophthalmology. 2012;119(4):674–81.PubMedCrossRef
45.
Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California. Davis. Ophthalmology. 2011;118(8):1543–50.PubMedCrossRef
46.
Klufas MA, Yannuzzi NA, D’Amico DJ, Kiss S Vitreoretinal aspects of permanent keratoprosthesis. Surv Ophthalmol. 2015;60(3):216–28.
47.
Robert M-C, Moussally K, Harissi-Dagher M. Review of endophthalmitis following Boston keratoprosthesis type 1. Br J Ophthalmol. 2012;96(6):776–80.PubMedCrossRef
48.
Durand ML, Dohlman CH. Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea. 2009;28(8):896–901.PubMedCrossRef
49.
Chew HF, Ayres BD, Hammersmith KM, Rapuano CJ, Laibson PR, Myers JS, et al. Boston keratoprosthesis outcomes and complications. Cornea. 2009;28(9):989–96.PubMedCrossRef
50.
Scott IU, Flynn HW, Feuer W, Pflugfelder SC, Alfonso EC, Forster RK, et al. Endophthalmitis associated with microbial keratitis. Ophthalmology. 1996;103(11):1864–70.PubMedCrossRef
51.
O’Neill EC, Yeoh J, Fabinyi DC, Cassidy D, Vajpayee RB, Allen P, et al. Risk factors, microbial profiles and prognosis of microbial keratitis-associated endophthalmitis in high-risk eyes. Graefe’s Arch Clin Exp Ophthalmol. 2014;252(9):1457–62.CrossRef
52.
Henry CR, Flynn HW, Miller D, Forster RK, Alfonso EC. Infectious keratitis progressing to endophthalmitis: a 15-year study of microbiology, associated factors, and clinical outcomes. Ophthalmology. 2012;119(12):2443–9.PubMedPubMedCentralCrossRef
53.
Bharathi MJ, Ramakrishnan R, Shivakumar C, Meenakshi R, Lionalraj D. Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India. Indian J Ophthalmol. 2010;58(6):497.PubMedPubMedCentralCrossRef
54.
55.
Eifrig CW, Scott IU, Flynn HW, Smiddy WE, Newton J. Endophthalmitis after pars plana vitrectomy: incidence, causative organisms, and visual acuity outcomes. Am J Ophthalmol. 2004;138(5):799–802.PubMedCrossRef
56.
Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS. Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology. Ophthalmology. 2010;117(9):1851–7.PubMedCrossRef
57.
Scott IU, Flynn HW Jr, Acar N, Dev S, Shaikh S, Mittra RA, et al. Incidence of endophthalmitis after 20-gauge vs 23-gauge vs 25-gauge pars plana vitrectomy. Graefe’s Arch Clin Exp Ophthalmol. 2011;249(3):377–80.CrossRef
58.
Scott IU, Harry W, Flynn J, Dev S, Shaikh S, Mittra RA, Arevalo JF, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina. 2008;28(1):138–42.PubMedCrossRef
59.
Hu AY, Bourges J-L, Shah SP, Gupta A, Gonzales CR, Oliver SC, et al. Endophthalmitis after pars plana vitrectomy: a 20-and 25-gauge comparison. Ophthalmology. 2009;116(7):1360–5.PubMedCrossRef
60.
Kunimoto DY, Kaiser RS, Service WER. Incidence of endophthalmitis after 20-and 25-gauge vitrectomy. Ophthalmology. 2007;114(12):2133–7.CrossRef
61.
Shah RE, Gupta O. The microsurgical safety task force: guidelines for minimizing endophthalmitis with vitrectomy surgery. Curr Opin Ophthalmol. 2012;23(3):189–94.PubMedCrossRef
62.
Oshima Y, Kadonosono K, Yamaji H, Inoue M, Yoshida M, Kimura H, et al. Multicenter survey with a systematic overview of acute-onset endophthalmitis after transconjunctival microincision vitrectomy surgery. Am J Ophthalmol. 2010;150(5):716–25. e1.
63.
Bahrani HM, Fazelat AA, Thomas M, Hirose T, Kroll AJ, Lou PL, Ryan EA. Endophthalmitis in the era of small gauge transconjunctival sutureless vitrectomy-meta analysis and review of literature. Semin Ophthalmol. 2010;25(5–6):275–82.PubMedCrossRef
64.
Govetto A, Virgili G, Menchini F, Lanzetta P, Menchini U. A systematic review of endophthalmitis after microincisional versus 20-gauge vitrectomy. Ophthalmology. 2013;120(11):2286–91.PubMedCrossRef
65.
Wu L, Berrocal MH, Arévalo JF, Carpentier C, Rodriguez FJ, Alezzandrini A, et al. Endophthalmitis after pars plana vitrectomy: results of the Pan American Collaborative Retina Study Group. Retina. 2011;31(4):673–8.PubMedCrossRef
66.
Chiang A, Kaiser RS, Avery RL, Dugel PU, Eliott D, Shah SP, et al. Endophthalmitis in microincision vitrectomy: outcomes of gas-filled eyes. Retina. 2011;31(8):1513–7.PubMedCrossRef
67.
Venkatesh P, Verma L, Tewari H. Posterior vitreous wick syndrome: a potential cause of endophthalmitis following vitreo-retinal surgery. Med Hypotheses. 2002;58(6):513–5.PubMedCrossRef
68.
Singh A, Chen JA, Stewart JM. Ocular surface fluid contamination of sutureless 25-gauge vitrectomy incisions. Retina. 2008;28(4):553–7.PubMedCrossRef
69.
Cochereau I. Endophthalmitis following new procedures. J Fr Ophtalmol. 2007;30(10):1067–9.
70.
Park JC, Ramasamy B, Shaw S, Prasad S, Ling RH, Foot B, et al. A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy: incidence and risk factors. Br J Ophthalmol. 2014;98(4):529–33.PubMedCrossRef
71.
Bacon AS, Davison CR, Patel BC, Frazer DG, Ficker LA, Dart J. Infective endophthalmitis following vitreoretinal surgery. Eye. 1993;7(pt 4):529–34.PubMedCrossRef
72.
Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011;151(5):887–95. e1.
73.
74.
Lyall D, Tey A, Foot B, Roxburgh S, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye. 2012;26(12):1517–26.PubMedPubMedCentralCrossRef
75.
76.
Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica. 2011;226(3):145–50.PubMedCrossRef
77.
Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266–72.PubMedPubMedCentralCrossRef
78.
Englander M, Chen TC, Paschalis EI, Miller JW, Kim IK. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol. 2013;97(4):460–5.PubMedCrossRef
79.
Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, Schwartz SG, Davis JL, Murray TG, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a University Referral Center. Retina. 2011;31(4):662–8.PubMedCrossRef
80.
Hoevenaars N, Gans D, Missotten T, van Rooij J, Lesaffre E, Van Meurs J. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: case series and literature review. Ophthalmologica. 2012;228(3):143–7.PubMedCrossRef
81.
Goldberg RA, Flynn HW, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–8. e1.
82.
Mccannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti–vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–61.PubMedCrossRef
83.
Vaziri K, Schwartz SG, Kishor K, Flynn Jr HW. Endophthalmitis: state of the art. Clin Ophthalmol (Auckl, NZ). 2015;9:95.
84.
Scott IU, Flynn HW, Feuer W. Endophthalmids after secondary intraocular lens implantation: a case–control study. Ophthalmology. 1995;102(12):1925–31.PubMedCrossRef
85.
Friedman DA, Mason JO III, Emond T, Mcgwin G Jr. Povidone–iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975–81.PubMedCrossRef
86.
Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophthalmol. 2014;157(3):514–8. e1.
87.
Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol. 2007;27(5):307–12.PubMedCrossRef
88.
Bhavsar A, Googe J Jr, Stockdale C, Bressler N, Brucker A, Elman M, et al. Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009;127(12):1581–3.PubMedPubMedCentralCrossRef
89.
Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–14.PubMedCrossRef
90.
Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329–32.PubMedCrossRef
91.
Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879–82.PubMedCrossRef
92.
Webster J, Alghamdi A. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev. 2007;4:CD006353.
93.
Tailor R, Beasley R, Yang Y, Narendran N. Evaluation of patients’ experiences at different stages of the intravitreal injection procedure–what can be improved? Clin Ophthalmol (Auckl, NZ). 2011;5:1499.
94.
Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone–iodine irrigation and surgical mask. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(8):1885–90.
95.
Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34(5):951–7.PubMedCrossRef
96.
Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina. 2012;32(3):473–6.PubMed
97.
Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551–4.PubMedCrossRef
98.
Shah C, Garg S, Vander J, Brown G, Kaiser R, Haller J. Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028–34.PubMedCrossRef
99.
Fineman MS, Hsu J, Spirn MJ, Kaiser RS. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33(9):1968–70.PubMedCrossRef
100.
Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, D’Amico DJ, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34:S1–18.PubMedCrossRef
101.
Charles QY, Ta CN. Prevention and treatment of injection-related endophthalmitis. Graefe’s Arch Clin Exp Ophthalmol. 2014;252(7):1027–31.
102.
Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991;98(7):1053–60.PubMedCrossRef
103.
DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297–300.PubMedCrossRef
104.
Vaziri K, Kishor K, Schwartz SG, Maharaj AS, Moshfeghi DM, Moshfeghi AA, et al. Incidence of bleb-associated endophthalmitis in the United States. Clin Ophthalmol (Auckl, NZ). 2015;9:317.
105.
Jampel HD, Quigley HA, Kerrigan-Baumrind LA, Melia BM, Friedman D, Barron Y. Risk factors for late-onset infection following glaucoma filtration surgery. Arch Ophthalmol. 2001;119(7):1001–8.PubMedCrossRef
106.
Soltau JB, Rothman RF, Budenz DL, Greenfield DS, Feuer W, Liebmann JM, et al. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol. 2000;118(3):338–42.PubMedCrossRef
107.
Mochizuki K, Jikihara S, Ando Y, Hori N, Yamamoto T, Kitazawa Y. Incidence of delayed onset infection after trabeculectomy with adjunctive mitomycin C or 5-fluorouracil treatment. Br J Ophthalmol. 1997;81(10):877–83.PubMedPubMedCentralCrossRef
108.
Leng T, Miller D, Flynn HW Jr, Jacobs DJ, Gedde SJ. Delayed-onset bleb-associated endophthalmitis (1996–2008): causative organisms and visual acuity outcomes. Retina. 2011;31(2):344–52.PubMedCrossRef
109.
Wallin Ö, Al-ahramy AM, Lundström M, Montan P. Endophthalmitis and severe blebitis following trabeculectomy. Epidemiology and risk factors; a single-centre retrospective study. Acta Ophthalmol. 2014;92(5):426–31.PubMedCrossRef
110.
Al-Turki TA, Al-Shahwan S, Al-Mezaine HS, Kangave D, Abu El-Asrar AM. Microbiology and visual outcome of bleb-associated endophthalmitis. Ocul Immunol Inflamm. 2010;18(2):121–6.PubMedCrossRef
111.
Brown RH, Yang LH, Walker SD, Lynch MG, Martinez LA, Wilson LA. Treatment of bleb infection after glaucoma surgery. Arch Ophthalmol. 1994;112(1):57–61.PubMedCrossRef
112.
Chen PP, Gedde SJ, Budenz DL, Parrish RK. Outpatient treatment of bleb infection. Arch Ophthalmol. 1997;115(9):1124–8.PubMedCrossRef
113.
Reynolds AC, Skuta GL, Monlux R, Johnson J. Management of blebitis by members of the American Glaucoma Society: a survey. J Glaucoma. 2001;10(4):340–7.PubMedCrossRef
114.
Song A, Scott IU, Flynn MHW, Budenz DL. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology. 2002;109(5):985–91.PubMedCrossRef
115.
Busbee BG, Recchia FM, Kaiser R, Nagra P, Rosenblatt B, Pearlman RB. Bleb-associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology. 2004;111(8):1495–503.PubMedCrossRef
116.
Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the tube versus trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804–14.e1.
117.
Al-Torbak A, Al-Shahwan S, Al-Jadaan I, Al-Hommadi A, Edward D. Endophthalmitis associated with the Ahmed glaucoma valve implant. Br J Ophthalmol. 2005;89(4):454–8.PubMedPubMedCentralCrossRef
118.
Fan JC, Niederer RL, Von Lany H, Polkinghorne PJ. Infectious endophthalmitis: clinical features, management and visual outcomes. Clin Exp Ophthalmol. 2008;36(7):631–6.
119.
Andreoli CM, Andreoli MT, Kloek CE, Ahuero AE, Vavvas D, Durand ML. Low rate of endophthalmitis in a large series of open globe injuries. Am J Ophthalmol. 2009;147(4):601–8. e2.
120.
Chhabra S, Kunimoto DY, Kazi L, Regillo CD, Ho AC, Belmont J, et al. Endophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolates. Am J Ophthalmol. 2006;142(5):852–4.PubMedCrossRef
121.
Faghihi H, Hajizadeh F, Esfahani MR, Rasoulinejad SA, Lashay A, Mirshahi A, et al. Posttraumatic endophthalmitis: report No. 2. Retina. 2012;32(1):146–51.PubMedCrossRef
122.
Zhang Y, Zhang M, Jiang C, Yao Y, Zhang K. Endophthalmitis following open globe injury. Br J Ophthalmol. 2010;94(1):111–4.PubMedCrossRef
123.
Essex RW, Yi Q, Charles PG, Allen PJ. Post-traumatic endophthalmitis. Ophthalmology. 2004;111(11):2015–22.PubMedCrossRef
124.
Al-Omran AM, Abboud EB, El-Asrar AMA. Microbiologic spectrum and visual outcome of posttraumatic endophthalmitis. Retina. 2007;27(2):236–42.
125.
Bhagat N, Nagori S, Zarbin M. Post-traumatic infectious endophthalmitis. Surv Ophthalmol. 2011;56(3):214–51.PubMedCrossRef
126.
Al-Rashaed SA, Abu El-Asrar AM. Exogenous endophthalmitis in pediatric age group. Ocul Immunol Inflamm. 2006;14(5):285–92.PubMedCrossRef
127.
Vedantham V, Nirmalan PK, Ramasamy K, Prakash K, Namperumalsamy P. Clinico-microbiological profile and visual outcomes of post-traumatic endophthalmitis at a tertiary eye care center in South India. Indian J Ophthalmol. 2006;54(1):5.PubMedCrossRef
128.
Das T, Choudhury K, Sharma S, Jalali S, Nuthethi R, Endophthalmitis Research Group. Clinical profile and outcome in Bacillus endophthalmitis. Ophthalmology. 2001;108(10):1819–25.PubMedCrossRef
129.
Callegan MC, Kane ST, Cochran DC, Novosad B, Gilmore MS, Gominet M, et al. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005;46(9):3233–8.PubMedCrossRef
130.
Gupta A, Srinivasan R, Kaliaperumal S, Saha I. Post-traumatic fungal endophthalmitis—a prospective study. Eye. 2008;22(1):13–7.PubMedCrossRef
131.
Schmidseder E, de Kaspar HM, Kampik A, Klauß V. Post-traumatic endophthalmitis after penetrating eye injury. Risk factors, microbiological diagnosis and functional outcome. Ophthalmolge. 1998;95(3):153–7.CrossRef
132.
Woodcock MG, Scott RA, Huntbach J, Kirkby GR. Mass and shape as factors in intraocular foreign body injuries. Ophthalmology. 2006;113(12):2262–9.PubMedCrossRef
133.
Soheilian M, Rafati N, Mohebbi M-R, Yazdani S, Habibabadi HF, Feghhi M, et al. Prophylaxis of acute posttraumatic bacterial endophthalmitis: a multicenter, randomized clinical trial of intraocular antibiotic injection, report 2. Arch Ophthalmol. 2007;125(4):460–5.PubMedCrossRef
134.
135.
Sternberg P, Martin DF. Management of endophthalmitis in the post-endophthalmitis vitrectomy study era. Arch Ophthalmol. 2001;119(5):754–5.PubMedCrossRef
136.
Vaziri K, Pershing S, Albini TA, Moshfeghi DM, Moshfeghi AA. Risk factors predictive of endogenous endophthalmitis among hospitalized patients with hematogenous infections in the United States. Am J Ophthalmol. 2015;159(3):498–504.
137.
Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014;59(6):627–35.
138.
Shankar K, Gyanendra L, Hari S, Dev Narayan S. Culture proven endogenous bacterial endophthalmitis in apparently healthy individuals. Ocul Immunol Inflamm. 2009;17(6):396–9.PubMedCrossRef
139.
Wong J-S, Chan T-K, Lee H-M, Chee S-P. Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology. 2000;107(8):1483–91.PubMedCrossRef
140.
Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):403–23.PubMedCrossRef
141.
Chung KS, Kim YK, Song YG, Kim CO, Han SH, Chin BS, et al. Clinical review of endogenous endophthalmitis in Korea: a 14-year review of culture positive cases of two large hospitals. Yonsei Med J. 2011;52(4):630–4.PubMedPubMedCentralCrossRef
142.
Okada AA, Johnson RP, Liles WC, D’Amico DJ, Baker AS. Endogenous bacterial endophthalmitis: report of a ten-year retrospective study. Ophthalmology. 1994;101(5):832–8.PubMedCrossRef
143.
Chen K-J, Hwang Y-S, Chen Y-P, Lai C-C, Chen T-L, Wang N-K. Endogenous Klebsiella endophthalmitis associated with Klebsiella pneumoniae pneumonia. Ocul Immunol Inflamm. 2009;17(3):153–9.PubMedCrossRef
144.
Takebayashi H, Mizota A, Tanaka M. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefe’s Arch Clin Exp Ophthalmol. 2006;244(7):816–20.CrossRef
145.
Connell P, O’Neill E, Fabinyi D, Islam F, Buttery R, McCombe M, et al. Endogenous endophthalmitis: 10-year experience at a tertiary referral centre. Eye. 2011;25(1):66–72.PubMedPubMedCentralCrossRef
146.
Shah C, McKey J, Spirn M, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008;92(4):466–8.PubMedCrossRef
147.
Riddell Iv J, Mcneil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine. 2002;81(4):311–20.
148.
Almeida DR, Miller D, Alfonso EC. Anterior chamber and vitreous concordance in endophthalmitis: implications for prophylaxis. Arch Ophthalmol. 2010;128(9):1136–9.PubMedCrossRef
149.
Bispo PJM, de Melo GB, Hofling-Lima AL, Pignatari ACC. Detection and gram discrimination of bacterial pathogens from aqueous and vitreous humor using real-time PCR assays. Invest Ophthalmol Vis Sci. 2011;52(2):873–81.PubMedCrossRef
150.
Sugita S, Kamoi K, Ogawa M, Watanabe K, Shimizu N, Mochizuki M. Detection of Candida and Aspergillus species DNA using broad-range real-time PCR for fungal endophthalmitis. Graefe’s Arch Clin Exp Ophthalmol. 2012;250(3):391–8.CrossRef
151.
Sridhar J, Flynn HW Jr, Kuriyan AE, Miller D, Albini T. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect. 2013;3(1):60.PubMedPubMedCentralCrossRef
Metadata
Title
Current Perspectives of Prophylaxis and Management of Acute Infective Endophthalmitis
Authors
Paris Tranos
Nikolaos Dervenis
Athanasios N. Vakalis
Solon Asteriadis
Panagiotis Stavrakas
Anastasios G. P. Konstas
Publication date
01-05-2016
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 5/2016
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-016-0307-8

Other articles of this Issue 5/2016

Advances in Therapy 5/2016 Go to the issue

Original Research

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary

Original Research

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials

Review

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma

Original Research

nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

Original Research

Laparoscopic Sleeve Gastrectomy Improves Excessive Daytime Sleepiness and Sleep Quality 6 Months Following Surgery: A Prospective Cohort Study

Original Research

FP/FORM Versus FP/SAL Within Clinical Practice: An Updated Budget Impact Analysis in Asthma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits